The AtTEnd clinical trial is for women with advanced stage or recurrent endometrial cancer and will assess whether the use of the immune therapy atezolizumab is of additional benefit to current, first line chemotherapy combination.
For most women with endometrial cancer, immune therapy alone is not an effective way of treating endometrial cancer. The addition of chemotherapy may improve the chance of immune therapy stimulating the body’s own immune system to fight and destroy the cancer cells.
AtTEnd is a double blind randomised placebo controlled trial of atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer.
AtTEnd is in collaboration with Mario Negri Gynecology Oncology Group (MaNGO) and the NHMRC CTC, and is currently recruiting at various clinical sites around Australia and New Zealand.
“The study is helping to answer a very important question about the role of immune therapy in non-mismatch repair-deficient tumours, by also seeking to improve the outcomes for women with advanced endometrial cancer.”
AtTEnd Principal Investigator, Associate Professor Yoland Antill
